Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Liquidia Technologies, boosting the price target to $54.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight the promising start of Liquidia Technologies’ product, Yutrepia, in the market. The company has demonstrated a strong initial launch for Yutrepia, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, achieving over 900 unique prescriptions and more than 550 patient starts in just 11 weeks, resulting in $6.5 million in revenue. This rapid uptake is supported by the signing of contracts with major pharmacy benefit managers, which typically takes much longer, indicating a significant reduction in launch hurdles.
Cory Jubinville, PhD’s rating is also based on the positive feedback from prescribers, with over 350 out of a target of 6,500 already prescribing Yutrepia. This suggests strong interest from the medical community and potential for further growth as doctors introduce the treatment to more patients during regular visits. Additionally, Liquidia’s efforts to expand manufacturing capacity and the financial health of the company, despite a high short interest, further support the Buy rating, as these factors contribute to the company’s ability to sustain and grow its market presence.
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Liquidia Technologies, and Rocket Pharmaceuticals. According to TipRanks, Jubinville, PhD has an average return of 2.8% and a 45.45% success rate on recommended stocks.